🇺🇸 FDA
Pipeline program

0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection

ACE-536-MF-002

Phase 3 small_molecule active

Quick answer

0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection for Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is a Phase 3 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Celgene Europe Limited
Indication
Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials